A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
NCT ID: NCT06294912
Last Updated: 2025-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2024-04-18
2025-01-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes
NCT02090036
MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B
NCT02783833
Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A
NCT02783820
Phase2a Primaquine Dose Escalation Study
NCT01743820
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
NCT02974348
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Panel A: MK-7602 Single dose Part 1
Participants are inoculated with Plasmodium falciparum (P. falciparum). Panel A participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
Plasmodium falciparum
Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
MK-7602
Capsules to be administered orally.
Artemether/lumefantrine
Tablets to be administered orally as definitive antimalarial treatment.
Primaquine
Tablets to be administered orally as definitive antimalarial treatment.
Artesunate
Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Atovaquone/proguanil
Tablets to be administered orally as definitive antimalarial treatment.
Panel B: MK-7602 Single dose Part 1
Participants are inoculated with P. falciparum. Panel B participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
Plasmodium falciparum
Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
MK-7602
Capsules to be administered orally.
Artemether/lumefantrine
Tablets to be administered orally as definitive antimalarial treatment.
Primaquine
Tablets to be administered orally as definitive antimalarial treatment.
Artesunate
Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Atovaquone/proguanil
Tablets to be administered orally as definitive antimalarial treatment.
Panel C: MK-7602 Single dose Part 1
Participants are inoculated with P. falciparum. Panel C participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
Plasmodium falciparum
Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
MK-7602
Capsules to be administered orally.
Artemether/lumefantrine
Tablets to be administered orally as definitive antimalarial treatment.
Primaquine
Tablets to be administered orally as definitive antimalarial treatment.
Artesunate
Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Atovaquone/proguanil
Tablets to be administered orally as definitive antimalarial treatment.
Panel D: MK-7602 Single dose Part 1
Participants are inoculated with P. falciparum. Panel D participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
Plasmodium falciparum
Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
MK-7602
Capsules to be administered orally.
Artemether/lumefantrine
Tablets to be administered orally as definitive antimalarial treatment.
Primaquine
Tablets to be administered orally as definitive antimalarial treatment.
Artesunate
Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Atovaquone/proguanil
Tablets to be administered orally as definitive antimalarial treatment.
Panel E: MK-7602 Single dose Part 1
Participants are inoculated with P. falciparum. Panel E participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
Plasmodium falciparum
Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
MK-7602
Capsules to be administered orally.
Artemether/lumefantrine
Tablets to be administered orally as definitive antimalarial treatment.
Primaquine
Tablets to be administered orally as definitive antimalarial treatment.
Artesunate
Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Atovaquone/proguanil
Tablets to be administered orally as definitive antimalarial treatment.
Panel F: MK-7602 Multiple dose Part 2
Participants are inoculated with P. falciparum. Panel F participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
Plasmodium falciparum
Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
MK-7602
Capsules to be administered orally.
Artemether/lumefantrine
Tablets to be administered orally as definitive antimalarial treatment.
Primaquine
Tablets to be administered orally as definitive antimalarial treatment.
Artesunate
Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Atovaquone/proguanil
Tablets to be administered orally as definitive antimalarial treatment.
Panel G: MK-7602 Multiple dose Part 2
Participants are inoculated with P. falciparum. Panel G participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
Plasmodium falciparum
Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
MK-7602
Capsules to be administered orally.
Artemether/lumefantrine
Tablets to be administered orally as definitive antimalarial treatment.
Primaquine
Tablets to be administered orally as definitive antimalarial treatment.
Artesunate
Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Atovaquone/proguanil
Tablets to be administered orally as definitive antimalarial treatment.
Panel H: MK-7602 Multiple dose Part 2
Participants are inoculated with P. falciparum. Panel H participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
Plasmodium falciparum
Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
MK-7602
Capsules to be administered orally.
Artemether/lumefantrine
Tablets to be administered orally as definitive antimalarial treatment.
Primaquine
Tablets to be administered orally as definitive antimalarial treatment.
Artesunate
Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Atovaquone/proguanil
Tablets to be administered orally as definitive antimalarial treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasmodium falciparum
Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
MK-7602
Capsules to be administered orally.
Artemether/lumefantrine
Tablets to be administered orally as definitive antimalarial treatment.
Primaquine
Tablets to be administered orally as definitive antimalarial treatment.
Artesunate
Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Atovaquone/proguanil
Tablets to be administered orally as definitive antimalarial treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has a body mass index (BMI) between 18 and 32 kg/m2, inclusive
* For participant assigned male sex at birth: If capable of producing sperm, participant must agree to the following during the study treatment period and for at least 90 days after the last dose of MK-7602: Refrain from donating sperm, plus EITHER be abstinent OR must agree to use male condom plus additional contraceptive method
* For participant assigned female sex at birth: EITHER be a person of nonchildbearing potential (PONCBP) OR must use a highly effective contraceptive method or be abstinent during the intervention period and for at least 10 days after the last dose of study intervention
* Must provide confirmation of not living alone (at any stage from inoculation day until the end of the study). A participant who lives alone may be included on a case-by-case basis.
* Agrees to refrain from eating food containing poppy seeds for 48 hours prior to screening, malaria inoculation, and MK-7602 administration
Exclusion Criteria
* Is mentally or legally incapacitated or has a history of clinically significant psychiatric disorder
* History of cancer (malignancy)
* History of malaria
* History of splenectomy
* History of ever receiving a blood transfusion
* History of recurrent headache (eg, tension-type, cluster or migraine) with a frequency of ≥2 episodes per month on average and severe enough to require medical therapy, during the 5 years preceding the screening visit
* History of convulsion (including intravenous drug or vaccine-induced episodes). A medical history of a single febrile convulsion during childhood is not considered an exclusion criterion.
* Has presence of clinically significant infectious disease or fever (eg, sublingual temperature ≥38.5 degrees Celsius) within the 5 days prior to inoculation
* Has evidence of acute illness within the 4 weeks prior to screening that the Investigator deems may compromise participant safety
* Has clinically significant disease or any condition or disease that might affect drug absorption, distribution, or excretion (eg, gastrectomy, diarrhea)
* Has a medical requirement for intravenous immunoglobulin or blood transfusions
* Has had a major surgery with more than 470 mL of blood loss, lost 1 unit of blood (approximately 470 mL) or undergone blood donation of any volume to the Australian Red Cross Blood Service (Blood Service) or other blood blank within 4 weeks prior to the prestudy screening visit) or during the 8 weeks prior to inoculation
* Has used any corticosteroids, anti-inflammatory drugs (excluding commonly used over-the-counter anti-inflammatory drugs such as ibuprofen, acetylsalicylic acid, diclofenac), immunomodulators or anticoagulants within the past three months
* History of receiving immunosuppressive therapy (including systemic steroids, adrenocorticotrophic hormone, or inhaled steroids) at a dose or duration potentially associated with hypothalamic-pituitary-adrenal axis suppression within the past year from the screening visit
* Has had any vaccination within the last 28 days
* Has participated in another investigational study within 12 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit
* History of participation in a previous malaria challenge study or malaria vaccine study.
* Must not have had malaria exposure that is considered by the principal investigator or their delegate to be significant
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USC Clinical Trials Brisbane (South Bank) ( Site 0001)
South Brisbane, South Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-7602-003
Identifier Type: OTHER
Identifier Source: secondary_id
7602-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.